GYRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gyre Therapeutics Inc (GYRE) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has bearish technical indicators, and no significant trading signals from Intellectia Proprietary Trading Signals. While the company has shown revenue growth and an improvement in net income, the financials are still negative, and there is no recent news or analyst activity to support a strong buy recommendation.
The technical indicators show a bearish trend with moving averages indicating downward momentum (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 50.465, and the MACD is slightly positive but not strong enough to suggest a clear upward trend. The stock is trading near its pivot level of 6.969, with resistance at 7.259 and support at 6.678.
The company reported a 33.45% YoY revenue increase and a significant improvement in net income (-1723000, up 1640.40% YoY).
No recent news, no significant hedge fund or insider trading activity, no recent congress trading data, and bearish technical indicators. The gross margin slightly declined (-0.49% YoY), and the stock has no strong trading signals.
In Q4 2025, revenue increased to $37,195,000 (up 33.45% YoY), net income improved significantly to -$1,723,000 (up 1640.40% YoY), and EPS remained at -0.02 (no change YoY). Gross margin dropped slightly to 95.31% (-0.49% YoY).
No recent analyst ratings or price target changes available.
